PathAI has introduced the AIM-IHC Breast Panel, an advanced set of AI-assisted algorithms designed to quantify critical breast cancer biomarkers including HER2, ER, PR, and Ki-67 with unprecedented accuracy and consistency. This tool, now available on PathAI's AISight® Image Management System, addresses the pressing need for standardized, reliable quantification methods to support pathologists in their critical work by providing accurate, consistent scoring directly from routine immunohistochemistry images.
The AIM-IHC Breast Panel performs automated tissue segmentation and detection of on-slide controls, differentiating between areas of invasive and non-invasive cancer while providing overlays to support algorithmic scoring. This breast cancer-centric approach enhances pathologist workflow by allowing better differentiation of regions of interest and improving the accuracy of invasive cancer segmentation. The technology represents a significant step forward in addressing challenges associated with breast cancer biomarker quantification, particularly for traditionally time-consuming processes like Ki-67 scoring where pathologists previously spent significant time manually counting cells or relying on imprecise approximations.
Andrew Beck, CEO of PathAI, emphasized the company's commitment to advancing precision pathology, stating that they are empowering pathologists with tools to make more accurate, consistent, and efficient assessments. The panel's automated features include classification of invasive cancer and generation of percentage-based results for positive cancer cells, providing pathologists with the clarity needed to produce more accurate scoring. This technology is part of PathAI's expanding suite of AI-powered solutions on the AISight® IMS, which serves as a central hub for managing pathology images and enables seamless integration of various AI-driven tools for pathology labs.
The implications of this technology extend beyond individual pathology labs, with the potential to enhance the overall quality of breast cancer diagnostics and research by improving accuracy and consistency of biomarker quantification. This could lead to more precise treatment decisions and better patient outcomes. While currently intended for research use only in the United States, the AISight Dx system has received CE-IVD marking in Europe, the UK, and Switzerland, indicating compliance with European regulations for in vitro diagnostic medical devices. As PathAI continues to expand its AIM-IHC Breast Panel and other AI-powered solutions, these advancements promise to streamline workflows, accelerate decision-making, and reduce time spent on manual tasks, allowing pathologists to focus more on complex cases and interpretations requiring human expertise.
